Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01181089
  4. Details
NCT01181089 Clinical Trial

Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

Secondary Progressive Multiple Sclerosis Clinical Trial

Official title:
A Multicenter, Randomized, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF) and Safety in Subjects With Secondary Progressive Multiple Sclerosis

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT01181089
Other study ID # 104MS101
Secondary ID
Status Withdrawn
Phase Phase 1/Phase 2
First received August 5, 2010
Last updated September 12, 2013
Start date September 2010

Study information
Verified date January 2012
Source Biogen
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory AgencyUnited Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

This is a prospective, randomized, multicenter, dose escalation study to determine subject safety, pharmacokinetic, and pharmacodynamic responses in patients with SPMS

Description:

This study is a prospective, randomized, placebo-controlled, blinded, dose escalation study of 3 to 4 cohorts with defined number of patients per cohort receiving active drug or placebo for a period of 4 months followed by safety monitoring for an additional 4 months after the last dose

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 57 Years
Eligibility Inclusion Criteria:

- A diagnosis of Secondary Progressive Multiple Sclerosis

- Aged 18 to 57 years old, at the time of informed consent

Exclusion Criteria:

- History of clinically important (as determined by the investigator) cardiac, endocrinologic, pulmonary, neurologic, immune, psychiatric, hepatic, renal or hematologic insufficiency or any other major disease other than MS ( Multiple Sclerosis)

- Inability in the opinion of the Investigator to comply with study requirements

- Other protocol-defined criteria may apply

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Biological:
• Placebo

• Baminercept

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Biogen

Outcome
Type Measure Description Time frame Safety issue
Primary Measure: Change in cerebrospinal fluid levels of secondary lymphoid organs chemokines from baseline with baminercept relative to placebo after 4 months of treatment No
Secondary Number of subjects experiencing Serious Adverse Event (SAE) and Adverse Event (AE) with baminercept relative to placebo 8 months (4 months on drug, 4 months post-drug) Yes
See also
  Status Clinical Trial Phase
Completed NCT04239664 - Acceptance Based Telephone Support When Transitioning to SPMS N/A
Active, not recruiting NCT04411641 - Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) Phase 3
Completed NCT02549703 - Mitochondrial Dysfunction and Disease Progression
Terminated NCT01416181 - A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis Phase 3
Active, not recruiting NCT03471338 - Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme N/A
Withdrawn NCT05029609 - Phase 1b Multiple Ascending Dose Study of Foralumab in Primary and Secondary Progressive MS Phase 1
Completed NCT02228213 - Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis Phase 2
Terminated NCT02296346 - Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis N/A
Completed NCT00559702 - Safety Study of Natalizumab to Treat Multiple Sclerosis (MS) Phase 1
Terminated NCT03283826 - Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis Phase 1/Phase 2
Completed NCT02253264 - A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients Phase 1
Completed NCT01737372 - A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis N/A
Completed NCT00257855 - A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis Phase 2
Recruiting NCT06292923 - A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients Phase 2
Active, not recruiting NCT01228396 - AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Phase 2
Completed NCT03896217 - Simvastatin in Secondary Progressive Multiple Sclerosis Phase 2
Completed NCT02495766 - Autologous Mesenchymal Stromal Cells for Multiple Sclerosis Phase 1/Phase 2
Completed NCT00813969 - Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS Phase 1
Completed NCT01077466 - Natalizumab Treatment of Progressive Multiple Sclerosis Phase 2
Terminated NCT00146159 - Study Evaluating Mitoxantrone in Multiple Sclerosis Phase 3